<DOC>
	<DOCNO>NCT02846987</DOCNO>
	<brief_summary>The purpose study test good bad effect study drug call Abemaciclib . Abemaciclib could shrink cancer could also cause side effect . Researchers hope learn study drug delay growth cancer shrink cancer least one quarter compare present size . Abemaciclib FDA approve tested liposarcoma , shrunk tumor patient breast cancer , lymphoma , lung cancer .</brief_summary>
	<brief_title>Study Abemaciclib Dedifferentiated Liposarcoma</brief_title>
	<detailed_description />
	<mesh_term>Liposarcoma</mesh_term>
	<criteria>A diagnosis dedifferentiate liposarcoma confirm MSKCC . Metastatic and/or locally advance locally recurrent disease surgically resectable . All patient must measurable disease define RECIST 1.1 . Patients must also evidence disease progression RECIST 1.1 within 6 month first dose study drug . Any number prior therapy ( include none ) permit . The last dose systemic therapy ( include target therapy ) must give least 2 4 week prior initiation therapy . Patients receive BCNU mitomycin C must receive last dose therapy least 6 week prior initiation therapy . Patients brain metastasis treat definitive surgery radiation clinically stable 3 month eligible . Age ≥ 18 year . ECOG performance status 0 1 Adequate organ marrow function define ( ULN indicate institutional upper limit normal ) : Absolute neutrophil count ≥ 1.510^9/L Hemoglobin ≥ 8.0 g/dL WBC ≥ 3.0 x 10^9/L Platelets ≥ 100 x 10^9/L Total bilirubin ≤ 1.5 x ULN except patient know Gilbert syndrome AST ( SGOT ) /ALT ( SGPT ) ≤ 3 x institutional ULN Creatinine ≤ 1.5 x ULN Creatinine Clearance &gt; 50 mL/min ( calculate CockcroftGault method ) Patients must current evidence another malignancy require treatment . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) . Women must breast feed study . Ability understand willingness sign write informed consent document . Ability swallow capsule Patients recover adverse event prior therapy ≤ NCI CTCAEv4.0 Grade 1 . Patients receive investigational agent . Patients receive prior treatment selective CDK4 inhibitor Uncontrolled intercurrent illness include , limited , know ongoing active infection , include HIV , active hepatitis B C , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia ( specifically , atrial fibrillation ventricular dysrhythmias except ventricular premature contraction ) , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman woman breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Abemaciclib</keyword>
	<keyword>LY2835219</keyword>
	<keyword>16-376</keyword>
</DOC>